drugset / Trial / NCT03774355

Study to Compare Safety and Pharmacokinetics of "CG1801" and "CGL1802" in Healthy Volunteers

NCT03774355

Phase 1 Completed 36 enrolled CrystalGenomics, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this open-label, randomized, 2\*2 crossover study is to compare the safety and Pharmacokinetics CG1801 and CGL1802 in Healthy Volunteers.

Timeline

Start
2018-12-17
Primary completion
2019-05-03
Completion
2019-05-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Polmacoxib Other / unclassified 2 mg

Indications

No indication recorded.